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Collagen, the most abundant component of extracellular matrix, is a mole-
cule of choice for the development of cellular biomaterials, because it can
interact with most cell types and can facilitate their adhesion and growth. In
this study, electrospun nanofibrous collagen patches was used to provide a
biocompatible physical support for the graft of human pluripotent stem cells
derived cardiomyocytes (hPCS-CM) for the treatment of the failing heart.
Different types of clinically approved collagen were studied for their ability
to form high quality uniform fibers by electrospinning using a benign solvent
system based on ethanol, water and salts. Atelocollagen – that contains 95% of
type I and 5% of type III – exhibited the best performance. After appropriate
crosslinking using cytocompatible agents based on citric acid (concentrated to
5% or 10%), the collagen was placed to special holders for cell culture.
The electrospun collagen patches were used for culture of newborn rats cardio-
myocytes, showing regular beating after 3 days of culture. They already have been
successfully used for the culture of hPSC-CM. Finally, the electrospun collagen
patches have been implanted in mice with dilated cardiomyopathy and have exhi-
bited excellent biocompatibility. Cardiac function measured by echocardiography
before and after the graft, histological, and molecular studies showed no detri-
mental effects of the collagen scaffold. Our next target is the implantation of
hPSC-CM-seeded scaffold in mice with dilated cardiomyopathy.
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The possibility to reboot the proliferation of adult resident cardiomyocytes
(CMs) has emerged as a promising avenue in cardiac regenerative medicine. For
that purpose, there is an urgent need for identifying the molecular mechanisms
involved in the natural blockage of adult CMs proliferation. Recently, we
recently demonstrated that ephrin-B1 expression in the CMs nuclei acts as a spe-
cific inhibitor of the adult CMs proliferation (unpublished data). Here, we have
explored the specific role of the PI3Kγ  in the nuclearization of ephrin-B1.
Fluorescent immunostaining showed a specific loss of nuclear ephrin-B1 in
p110-γ  KO but not in KI mice, suggesting a specific role of the PKA-
anchoring function of the p110-γ  catalytic subunit of PI3Kγ  in ephrin-B1
nuclearization. Interestingly, p110-γ  KO mice demonstrated a significant
increase of mononucleated CMs (19,1 ± 1,1 % vs 13,3 ± 1,0 % in WT) cor-
related to a decrease in binucleated CMs (70,9 ± 1,9 % vs 79,7 ±1,0 % in WT)
possibly indicative of a proliferative potential. In agreement with a prolifera-
tive potential, we measured a higher level of replicative-BrdU+ CMs in KO
PI3Kγ  mice (WT: 6,23±2,2 % ; KO: 19,3±4,9 %; KI: 3,0±0,8 %), but also a
higher CMs density in cardiac tissue from 8 month old mice (WT:
2633±79,4cm/mm²; KO: 3208±155,6CM/mm²; KI: 2659,7±99,3CM/mm²)
mosy likely reflecting CMs hyperplasia. To confirm the involvement of a
cAMP/PKA pathway in ephrin-B1 nuclearization, we studied a neonatal car-
diomyoblast cell line (H9C2) naturally expressing a nuclear ephrin-B1 pool.
We showed that H89 treatment prevented ephrin-B1 nuclearization while for-
skolin promoted nuclearization of a recombinant ephrin-B1-GFP.
These results demonstrated for the first time the specific role of the cAMP/
PKA/PI3Kγ  pathway in ephrin-B1 nuclearization in the CM. In the future, the
accurate characterization of this pathway could allow identifying new and
more specific targets for heart regenerative medicine strategies.
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Human pluripotent stem cells derived cardiomyoctyes are one the most
promising cells for cardiac research, i.e. disease modeling, drug screening and
cell therapy applications. Obtaining these cells is a critical step and has been
the subject of many studies and publications. Recent advances in this field
have shown that a sequential activation and inhibition of the Wnt pathway
induces the differentiation of human pluripotent stem cells toward the cardiac
lineage. This procedure can be achieved in a chemically-defined environment,
and beating cells are obtained after 8 days.
Several parameters of this protocol could still be improved. For example,
the small molecules used (Wnt activators and inhibitors) are not approved by
the health authorities, preventing their use in clinical studies. Moreover, there
are no standard procedures to recover the cardiomyocytes after the differenti-
ation protocol. Finally, late-stage differentiation to a totally matured ventri-
cular cardiomyocyte population has not been achieved for the moment. The
immature cardiac cells obtained have several differences compared to adult
cardiomyocytes. There are, for example, mismatches in cell size and shape,
gap junction, alignment and calcium handling ability. Raise these technolog-
ical barriers could lead to new perspectives in the use of these cells.
Our studies in this area have led us to develop innovative strategies to
obtain, recover and to mature these cells. We have tested several FDA-
approved drugs known to modulate the Wnt pathway in order to obtain a clin-
ical-grade population cardiomyocytes. We also determined, using a combina-
tion of protease, the condition of recovery allowing the best survival rate and
function of these cells. Finally, we improve the maturity of cardiomyocytes
derived from pluripotent stem cells by tuning their micro-environment. Our
results demonstrate the importance of the extracellular matrix composition and
mechanical properties.
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The possibility to reboot the proliferation of adult resident cardiomyo-
cytes (CM) has recently emerged as a new promising avenue in cardiac
regenerative medicine. For that purpose, there is an urgent need for identi-
fying the molecular mechanisms involved in the natural blockage of adult
CM proliferation.
We recently identified ephrin-B1 as specific stabilizer of the CM rod-shape
allowing the cardiac tissue cohesion. Interestingly, we found that ephrin-B1
knock-out mice (KO) compensate aging stress through a surprising CM hyper-
plasia, suggesting an atypical proliferation of adult CM. Cell cycle genes pro-
filing performed by qRT-PCR showed that old KO CM significantly up-
regulated genes involved in all cell cycle phases. Progression of CM
throughout the cell cycle was confirmed by flow cytometry and revealed the
presence of the replicative S-phase only in old KO CM. Proliferation was next
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directly assessed on isolated 2 months-old CM stimulated or not with neure-
gulin-1 growth factor. Remarkably, while this treatment resulted in 0.17% of
BrdU uptake in WT CM, it increased up to 9.57 % in KO. KO CM also exhib-
ited significant higher mitotic (pH3+) and cytokinesis (AuroraB+) events
compared to WT. Thus, the capacity for adult KO CM to proliferate is not
restricted to aged CM but more likely an intrinsic potential of young KO CM.
We next assessed the proliferative capacity of 2 month-old KO mice in vivo
using the apectomy model. Remarkably, while WT mice developed a classical
healing process (fibrosis/inflammation), KO mice almost completely regener-
ated the apex as indicated by the presence of mitotic (BrdU+, pH3+,
AuroraB+) CM and significant reduced fibrosis (50%) in the resected zone.
These results demonstrated that ephrin-B1 protein is a specific blocker of
adult CM proliferation and its downregulation represents a huge interest for
future therapeutic approaches in cardiac regenerative medicine.
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The Brain Natriuretic Peptide (BNP) is a cardiac hormone, which promotes
the recovery of cardiac function and the preservation of cardiac tissue in
animal models of heart diseases. Its cardiac protective role in animals was
attributed to fibrosis inhibition, as well as to reduction of cardiomyocyte apop-
tosis and hypertrophy. Recently, we demonstrated that BNP induces heart
regeneration via the stimulation of cardiac precursor cell (CPC) proliferation
and differentiation into mature cardiomyocytes.
The aim of our study was to identify which CPC’s subset is able to respond
to BNP stimulation.
Cardiac precursor cells identified as being Sca-1+ Nkx2.5+ or c-kit+ Nkx2.5+
cells, expressed in neonatal and adult hearts BNP’s receptors (NPR-A and
NPR-B), showing their ability to be activated by BNP treatment. Cell sorting
experiments based on the expression of Sca-1 or c-kit were performed on non-
myocyte cells isolated from neonatal wild-type hearts. Sca-1+ and c-kit+ cells
were cultured up to 3 weeks with or without BNP in differentiating medium.
Sca-1 positive cells, which contained few c-kit+ cells, responded clearly to
BNP stimulation by upregulating mRNA levels of genes coding for Nkx2.5,
Mlc-2v, c-kit, Sca-1, beta and alpha MHC. Furthermore, higher number of
Troponin I+ cells was detected in BNP treated cells compared to untreated
cells, suggesting that Sca-1+ cells differentiated after BNP stimulation into
mature cardiomyocytes. BNP treatment of c-kit+ cells didn’t induce the upreg-
ulation of mRNA coding for cardiomyocyte specific genes. However, we
determined that c-kit positive cells spontaneously differentiated into mature
cardiomyocytes during the 3 weeks of cell culture without BNP stimulation.
To determine which receptor is involved, Sca-1+ cells, isolated from neo-
natal hearts of NPR-A or NPR-B deficient mice, were treated with BNP. The
effects of BNP on wild type and NPR-A KO cells did not differ substantially.
However, Sca-1+ cells isolated from NPR-B deficient hearts couldn’t respond
anymore to BNP stimulation.
Thus, BNP specifically stimulates via NPR-B Sca-1+ cell differentiation
into cardiomyocytes. c-kit+ cells display clearly a cardiogenic potential which
is BNP independent.
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Breakthroughs in stem cell biology and demonstrations of the heart’s endog-
enous regenerative capacities have incited an intense race towards cardiac regen-
eration, i.e. the replacement of lost myocardium after myocardial infarction. In
preclinical trials, cell transplantation therapies, using adult human multipotent
stem cells (e. g, hematopoietic stem cells) into infarcted myocardium has shown
enhanced cardiogenesis in animal models. Nevertheless, results in clinical trials
remain unsatisfactory and determining a suitable cell population that is easily
harvested and improves cardiac repair is challenging.
In previous research, our lab isolated human peripheral blood mononuclear
clones (PBMCs) bearing cardiac mesodermal markers, e.g. c-kit, Islet-1 or
Flk-1. Potentially, these cells can differentiate within the cardiac lineage to
mature cardiomyocytes and participate in heart repair.
We sought to establish an in vitro cardioinstructive differentiation protocol to
derive cardiomyocytes from our PBMC population. For this, we screened three
differentiation protocols, i.e. Keller, Smith and He protocols. To follow cell dif-
ferentiation RT-qPCR and immunostainings were performed for relevant genes,
e.g. Nkx2.5, GATA4, Troponin T (cTNT), β-Myosin heavy chain (β-MHC) and
α-actinin. Results for mRNA expression showed that at least 75% of PBMCs
can derive to a cardiac precursor population (Nkx2.5+/GATA4+) following
Keller and Smith protocol. In Smith protocol, 75% of PBMCs differentiated to
immature cardiomyocytes (cTNT+) of which 50% expressed both cTNT and β-
MHC when co-cultured with neonatal mice ventricular myocytes. Immunofluo-
resence assay showed that PBMCs in both Keller and Smith protocol are
Nkx2.5+/α-actinin+ demonstrating differentiation at the protein level.
Next we evaluated the safety, survival and integration of injected PBMCs
in neonatal Gt(ROSA)26-Tomato mice tissues in vivo. By staining PBMC with
membrane marker PKH2GL, we followed cell homing within the animal tis-
sues visualized by fluorescent microscopy on tissue sections.
In conclusion, we demonstrated that human PBMCs can differentiate,
under certain conditions, into cardiac precursor cells or immature cardio-
myocytes in vitro. These results make them an interesting and promising cell
source for stem cell therapies in cardiac repair.
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Background: Cell therapy using intramyocardial injections of cardiac progen-
itors issued from human embryonic stem cells showed benefits on overloaded
right ventricular (RV) tissue remodelling and arrhythmic susceptibility but this
delivery mode failed to improve RV function. Our aim was to evaluate in a por-
cine model of overloaded RV dysfunction a new delivery mode of such therapy.
Methods: A combined overloaded RV dysfunction was obtained in piglets
using a surgical procedure mimicking repaired tetralogy of Fallot. After
4 months, cell therapy was surgically administrated using 2 types of human
NKX2.5+ cardiac progenitor cell-seeded collagen patches applied on the epi-
cardium: QGel® and pressured-patches. Myocardial function was measured
1 month after transplantation by conductance catheter technique and echocar-
diography (standard and strain). The fate of progenitors was studied using
antibodies directed against Ki67, CD31, actinin and Islet1.
Results: All pigs survived without any complication. Pressured-patches
allowed human progenitors to migrate across the complete myocardium while
QGel® patches restricted the cell migration to only a third of the myocardium.
In both cases, progenitors differentiated toward the cardiac lineage assessed by
Islet1 and actinin expression and maintained their proliferation capacity.
Concerning RV function, only pressured-patches (N=3) tended to improve the
contractility (Emax slope). By contrast, this parameter decreased in QGel®
patches animals (N=2). Moreover, in 2 pressured-patch animals, standard
echocardiographic functional parameters (FAC, TAPSE, s’wave) were main-
tained while 2D strain and strain rate values increased.
Conclusion: Cell therapy using seeded-patches was more conservative for
engrafted cells than intramyocardial injections but only pressured-patches
seemed to give benefits on overloaded RV function and contractility. These
first promising results need to be checked at longer term.
